Spine BioPharma Completes Series B Financing

Spine BioPharma completed a $13 million Series B equity financing. Proceeds will support further development of SB-01 For Injection (SB-01, formerly referred to as Remedisc™), a therapeutic for the treatment of degenerative disc disease.

SB-01 is a 7-amino acid chain peptide that binds to and induces downregulation of transforming growth factor,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us